[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity

Rhea-AI Filing Summary

PTC Therapeutics (PTCT) director reported Rule 10b5-1 trades. On 10/30/2025, the insider exercised 12,000 stock options at $38.1 per share and sold 12,000 common shares at $69.5. The filing also lists a separate sale of 3,666 shares at $69.5. After these transactions, the insider reported 6,666 shares held directly.

The trades were effected pursuant to a written Rule 10b5-1 plan adopted on March 4, 2025. The exercised options were currently exercisable and carry an expiration date of January 6, 2032.

Insights

Insider transactions analyst

Routine 10b5-1 option exercise and sales; neutral impact.

The filing shows a director exercised 12,000 options at $38.1 and sold 12,000 shares at $69.5, plus a separate sale of 3,666 shares, all on 10/30/2025. These actions were made under a Rule 10b5-1 plan adopted on March 4, 2025, indicating pre-set trading instructions.

Following the transactions, the insider reported holding 6,666 shares directly. This is an administrative disclosure; actual market impact depends on overall trading volume and holder activity. No company cash flows are indicated by these insider sales.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reeve Emma

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/30/2025		S(1)		3,666	D	$69.5	6,666	D
Common Stock	10/30/2025		M(1)		12,000	A	$38.1	18,666	D
Common Stock	10/30/2025		S(1)		12,000	D	$69.5	6,666	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$38.1	10/30/2025		M(1)			12,000	(2)	01/06/2032	Common Stock	12,000	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025.

2. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	10/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did PTCT report on 10/30/2025?

A director exercised 12,000 options at $38.1 and sold 12,000 shares at $69.5, plus a separate sale of 3,666 shares at $69.5.

How many PTCT shares does the insider hold after the transactions?

The insider reported 6,666 shares held directly after the reported transactions.

Were the PTCT trades under a Rule 10b5-1 plan?

Yes. The transactions were effected under a Rule 10b5-1 plan adopted on March 4, 2025.

What was the exercise price and expiration for the PTCT options?

The stock options had an exercise price of $38.1 and an expiration date of January 6, 2032; they were currently exercisable.

What sale prices were reported for PTCT shares?

Reported sales were at $69.5 per share.

Does PTCT receive proceeds from these insider sales?

Insider sales deliver proceeds to the seller; the filing shows an option exercise at $38.1 and share sales at $69.5.